Immutep (IMMP) Cash & Equivalents (2011 - 2025)

Immutep (IMMP) has 15 years of Cash & Equivalents data on file, last reported at $47.8 million in Q4 2025.

• Quarterly Cash & Equivalents fell 1.15% year-over-year to $47.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $47.8 million (down 1.15% YoY) and the FY2025 annual result came in at $43.2 million, down 59.51% from the prior year.
• Cash & Equivalents grew to $47.8 million in Q4 2025, from $43.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $106.6 million in Q2 2024 to a low of $43.2 million in Q2 2025.
• A 5-year average of $61.7 million and a median of $52.8 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents jumped 170.46% — and 2025, when it sank 59.51%.
• Tracing IMMP's Cash & Equivalents over 5 years: stood at $72.6 million in 2021, then sank by 38.12% to $44.9 million in 2022, then jumped by 50.32% to $67.5 million in 2023, then retreated by 28.45% to $48.3 million in 2024, then declined by 1.15% to $47.8 million in 2025.
• The last three Cash & Equivalents figures came in at $47.8 million (Q4 2025), $43.2 million (Q2 2025), and $48.3 million (Q4 2024), per Business Quant data.